Last reviewed · How we verify
Phase I Study to Determine the Safety of MS-209 in Combination With Docetaxel in Patients With a Solid Progressive Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of MS 209 plus docetaxel in treating patients who have advanced solid tumors.
Details
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 30 |
| Start date | 1999-12 |
Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
Interventions
- docetaxel
- dofequidar fumarate
Countries
France, Germany